Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07450157 · ClinicalTrials.gov registry record
A Study of Patient Characteristics, Treatment Patterns and Outcomes Among Patients Treated With 177Lu-PSMA-617
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 6,448
- Enrollment target
NCT07450157: Completed study, sponsored by Novartis Pharmaceuticals.
NCT07450157 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 6,448 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07450157 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 6,448 participants
- Enrollment target
Study Summary
The aim of this study was to evaluate patient characteristics, treatment patterns, prostate-specific antigen (PSA) reduction, and overall survival (OS) of prostate cancer patients treated with 177-Lutetium-Prostate-Specific Membrane Antigen-617 (177Lu-PSMA-617). Patient data from multiple electronic health record databases, including claims (open-source medical and pharmacy claims), consumer attributes, mortality, and laboratory data linked to claims databases was used. The study analysis was conducted in two phases. Phase I provided an early view of patients treated with 177Lu-PSMA-617 shortly after launch. Phase II refreshed the data, added mortality and extracted additional years of historical data to allow for the identification of the initial metastatic castrate-resistant prostate cancer (mCRPC) diagnosis and follow-up from that date through the start of 177Lu-PSMA-617.
Primary Outcome
Demographics included: * Age group * Geographical region * Payer type * Physician specialty * Race/ethnicity * Education level * Occupation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,448 participants |
| Start Date | 2023-06-23 |
| Est. Completion | 2025-02-28 |
What the finished NCT07450157 record still lists
NCT07450157 is an observational study that tracks outcomes without assigning an intervention. Its 6,448 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT07450157 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07450157 about?
NCT07450157 is a clinical study titled "A Study of Patient Characteristics, Treatment Patterns and Outcomes Among Patients Treated With 177Lu-PSMA-617". The aim of this study was to evaluate patient characteristics, treatment patterns, prostate-specific antigen (PSA) reduction, and overall survival (OS) of prostate cancer patients treated with 177-Lutetium-Prostate-Specific Membrane Antigen-617 (177Lu-PSMA-617). Patient data from multiple electronic...
What is the current status of trial NCT07450157?
This trial is currently completed. The enrollment target is 6,448 participants. The study started on 2023-06-23. Estimated completion is 2025-02-28.
Who is sponsoring clinical trial NCT07450157?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00505245 · 6,500 participants
New Assessment System in Measuring Symptom Distress in Cancer Patients
- NCT06821009 · 6,500 participants · NA
Effectiveness of a Cloud-based Digital Health Navigation Program for Colorectal Cancer Screening
- NCT05369429 · 6,516 participants · NA
My Wellbeing Guide: a Novel Tool for Managing Stress and Improving Quality of Life
- NCT05143697 · 6,600 participants · NA
Motivational Wellness Coaching to Reduce Childhood Obesity in Families and Kids
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI